Log in
Enquire now
‌

US Patent 9676840 Anti-CD100 neutralizing antibodies and methods of using the same

Patent 9676840 was granted and assigned to Vaccinex, Inc on June, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Patent abstract

Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9676840 Anti-CD100 neutralizing antibodies and methods of using the same

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.